• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[肺炎球菌大规模疫苗接种(PCV7)对波兰凯尔采全因肺炎发病率的间接人群效应]

[Indirect, population effect of mass pneumococcal vaccinations (PCV7) on all-cause pneumonia incidence in Kielce, Poland].

作者信息

Patrzałek Marian, Albrecht Piotr, Sobczyński Maciej

机构信息

NZOZ Promed w Kielcach.

出版信息

Przegl Epidemiol. 2011;65(1):51-6.

PMID:21735836
Abstract

In these article they made analysis of indirect, population effects of mass, free of charge, pneumococcal vaccinations (PCV7) on all-cause pneumonia incidence in Kielce, Poland. The strongest and significant fall (p=0.00079) in all-cause pneumonia incidence in the analyzed period 2005-2009 compared with remaining groups were observed in the group of children under 2 of years of life. He amounted to the 74% (around 25/1000 in 2005; 6/1000 in 2009). In the entire ancient group 0-29, embracing children under 2 yrs of life the fall of pneumonia incidence rate amounted to the 48% (from 2.8/1000 in 2005; 1.5/1000 in 2009). In the age 65+ group the fall in the incidence amounted to the 45% (19/1000 in 2005; <11/1000 in 2009 r.). At the moment they didn't observe, of such a fall in age groups 30-49 yrs and 50-64 yrs. Presented results are pointing population effectiveness of applied in Kielce mass vaccination in a 2+1 scheme. Analyzing only pneumonia requiring the hospitalization they tried at work to estimate, in the definitely simplified way, financial effects of mass pneumococcal vaccination in Kielce. Analysis showed at children up to 2 yrs frugalities of the row of the 174,420 zloty annually. In the group above 1 year of life analogous analysis showed frugalities of row 789,480 zloty. Results presented by us should, in our opinion, to induce decision-makers for free of charge mass pneumococcal vaccinations to entire Poland.

摘要

在这些文章中,他们分析了波兰凯尔采大规模免费肺炎球菌疫苗接种(PCV7)对全因肺炎发病率的间接人群效应。与其他组相比,在2005 - 2009年分析期内,2岁以下儿童组全因肺炎发病率出现了最强且显著的下降(p = 0.00079)。下降幅度达74%(2005年约为25/1000;2009年为6/1000)。在整个0 - 29岁年龄组(包括2岁以下儿童)中,肺炎发病率下降了48%(从2005年的2.8/1000降至2009年的1.5/1000)。在65岁及以上年龄组中,发病率下降了45%(2005年为19/1000;2009年降至<11/1000)。目前,在30 - 49岁和50 - 64岁年龄组未观察到这种下降情况。所呈现的结果表明了在凯尔采采用2 + 1方案进行大规模疫苗接种的人群有效性。仅分析需要住院治疗的肺炎病例时,他们试图以一种非常简化的方式估算凯尔采大规模肺炎球菌疫苗接种的财务影响。分析显示,2岁以下儿童每年节省174,420兹罗提。在1岁以上年龄组中,类似分析显示节省789,480兹罗提。我们认为,我们所呈现的结果应促使决策者在波兰全国范围内推行免费的大规模肺炎球菌疫苗接种。

相似文献

1
[Indirect, population effect of mass pneumococcal vaccinations (PCV7) on all-cause pneumonia incidence in Kielce, Poland].[肺炎球菌大规模疫苗接种(PCV7)对波兰凯尔采全因肺炎发病率的间接人群效应]
Przegl Epidemiol. 2011;65(1):51-6.
2
The cost-effectiveness of pneumococcal conjugate vaccination in Australia.澳大利亚肺炎球菌结合疫苗接种的成本效益
Vaccine. 2004 Mar 12;22(9-10):1138-49. doi: 10.1016/j.vaccine.2003.09.036.
3
Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.瑞士 13 价肺炎球菌结合疫苗的成本效益分析。
Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028. Epub 2012 Apr 20.
4
The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.瑞典小儿肺炎球菌疾病的成本负担以及使用7价肺炎球菌疫苗预防的潜在成本效益。
Vaccine. 2009 Mar 4;27(10):1601-8. doi: 10.1016/j.vaccine.2008.12.033. Epub 2009 Jan 13.
5
Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.挪威第二代肺炎球菌结合疫苗的经济学评价。
Vaccine. 2011 Nov 3;29(47):8564-74. doi: 10.1016/j.vaccine.2011.09.025. Epub 2011 Sep 21.
6
Indirect population impact of universal PCV7 vaccination of children in a 2 + 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland.2+1 程序下儿童普遍接种 PCV7 对波兰凯尔采肺炎发病率的间接人群影响。
Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3023-8. doi: 10.1007/s10096-012-1656-0. Epub 2012 Aug 16.
7
Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.意大利已接受 3 剂 7 价肺炎球菌结合疫苗儿童中 13 价肺炎球菌结合疫苗补种剂量的经济学和临床评价。
Vaccine. 2011 Nov 28;29(51):9521-8. doi: 10.1016/j.vaccine.2011.10.013. Epub 2011 Oct 18.
8
Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.香港地区可通过7价肺炎球菌结合疫苗预防的肺炎球菌疾病导致的儿科住院情况。
Vaccine. 2007 Sep 28;25(39-40):6837-41. doi: 10.1016/j.vaccine.2007.07.039. Epub 2007 Aug 7.
9
Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.尽管有肺炎球菌结合疫苗,美国儿童脓胸住院率仍在增加。
Pediatrics. 2010 Jan;125(1):26-33. doi: 10.1542/peds.2009-0184. Epub 2009 Nov 30.
10
Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).在加泰罗尼亚(西班牙)的常规疫苗接种计划中纳入7价肺炎球菌结合疫苗的成本效益和成本效果。
Vaccine. 2005 Mar 18;23(17-18):2342-8. doi: 10.1016/j.vaccine.2005.01.018.